A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder

References

• Panzarino PJ Jr, Nash DB. Cost-effective treatment of depressionwith selective serotonin reuptake inhibitors. Am J Manag Care 2001;7:173–84
   PubMed Web of Science ®Google Scholar
• Croom KF, Plosker GL. Spotlight on the pharmacoeconomics ofescitalopram in depression. Pharmacoeconomics 2004;18:469–73
   Google Scholar
• Arroll B, Macgillivray S, Ogston S, et al. Efficacy and tolerabilityof tricyclic antidepressants and SSRIs compared with placebofor treatment of depression in primary care: a meta-analysis.Ann Fam Med 2005;3:449–56
   PubMed Web of Science ®Google Scholar
• Lexapro® prescribing information. Forest Pharmaceuticals, Inc.Revised February 2005
   Google Scholar
• Cymbalta® prescribing information. Eli Lilly and Company. PV 3608 AMP
   Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economicburden of depression in the United States: how did it changebetween 1990 and 2000? J Clin Psychiatry 2003;64:1465–75
   PubMed Web of Science ®Google Scholar
• Croghan TW. The controversy of increased spending for antidepressants.Health Affairs 2001;20:129–35
   Web of Science ®Google Scholar
• Fochtmann LJ, Gelenberg AJ. Guideline watch: practice guidelinefor the treatment of patients with major depressive disorder, 2nd edition. Arlington, VA: American Psychiatric Association, 2005. Available from http://www.psych.org/psych_pract/treatg/pg/MDD.watch.pdf [Last accessed 19 Dec 2007]
   Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg oncedaily, for major depressive disorder: a randomized double-blindplacebo-controlled trial. J Clin Psychiatry 2002;63:308–15
   PubMed Web of Science ®Google Scholar
• Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine inthe acute and long-term treatment of major depressive disorder:a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457–70
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg oncedaily versus placebo in the acute treatment of major depression.J Psychiatric Res 2002;36:383–90
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatmentof depression. A double-blind placebo-controlled comparisonwith paroxetine. J Clin Psychopharmacol 2004;24:389–99
   PubMed Web of Science ®Google Scholar
• Burt VK, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine forthe treatment of major depressive disorder in women ages 40 to 55 years. Psychosomatics 2005;46:345–54
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetinein the treatment of major depressive disorder: a double-blindclinical trial. J Clin Psychiatry 2002;63:225–31
   PubMed Web of Science ®Google Scholar
• Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB.Duloxetine in the long-term treatment of major depressivedisorder. J Clin Psychiatry 2003;64:1237–44
   Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomerSSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331–6
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day)is effective and well tolerated in a placebo-controlled studyin depression in primary care. Internat Clin Psychopharmacol 2003;18: 211–7
   Google Scholar
• Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/dayis effective and well tolerated in a placebo-controlled study indepression in primary care. Clin Psychopharmacol 2002;17: 95–102
   Google Scholar
• Ventura D, Armstrong EP, Skrepnek GH, Erder MH.Escitalopram versus sertraline in the treatment of major depressivedisorder. A randomized clinical trial. Curr Med Res Opinion 2007;23:245–50
   Google Scholar
• Bech P, Tanghoj P, Cialdella P, et al. Escitalopram dose-responserevisited: an alternative psychometric approach to evaluate clinicaleffects of escitalopram compared to citalopram and placebo inpatients with major depression. Internat J Neuropsychopharmacol 2004;7:283–90
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Ventura D, Chang CC. A double-blind comparison ofescitalopram and venlafaxine extended release in the treatment ofmajor depressive disorder. J Clin Psychiatry 2004;65:1190–6
   Google Scholar
• Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram(20 mg/day) in primary care patients with major depressivedisorder. Curr Med Res Opinion 2005;21: 1659–68
   Google Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the costeffectiveness of escitalopram versus venlafaxine XR in majordepressive disorder. Pharmacoeconomics 2005;23:155–67
   Google Scholar
• Kasper S, Swart HD, Andersen HF. Escitalopram in thetreatment of depressed elderly patients. Am J Geriatr Psychiatry 2005;13:884–91
   PubMed Web of Science ®Google Scholar
• Lancon C, Sapin C, Note L, Farisse J. Escitalopram and citalopramin outpatients suffering from severe major depressivedisorder: a prospective, observational, eight-week study. Int JNeuropsychopharmacol 2004;7\(Suppl 1):S349 [abstract]
   Google Scholar
• Montgomery SA, Huusom AKT, Bothmer J. A randomized studycomparing escitalopram with venlafaxine XR in primary carepatients with major depressive disorder. Neuropsychobiology 2004;50:57–64
   Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre,randomized, double-blind study of the efficacy of escitalopramversus citalopram in outpatient treatment of major depressivedisorder. Int Clin Psychopharmacol 2005;20:131–7
   Google Scholar
• Rush AJ, Bose A. Escitalopram in clinical practice: results ofan open-label trial in a naturalistic setting. Depression Anxiety 2005;21:26–32
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparisonof the direct costs and cost effectiveness of serotonin reuptakeinhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911–32
   PubMed Web of Science ®Google Scholar
• McLaughlin TP, Eaddy MT, Grudzinski AN. A claims analysiscomparing citalopram with sertraline as initial pharmacotherapyfor a new episode of depression: impact on depression-relatedtreatment charges. Clin Ther 2004;26:115–24
   Google Scholar
• Physician fee schedule, Center for Medicare and MedicaidServices. Available from http://www.cms.hhs.gov/physicians/mpfsapp/step0.asp [Last accessed 3 Jan 2005]
   Google Scholar
• Einarson TR. Evidence based review of escitalopram intreating major depressive disorder in primary care. Int ClinPsychopharmacol 2004;19:305–10
   PubMed Web of Science ®Google Scholar
• Francois C, Sintonen H, Toumi M. Introduction of escitalopram,a new SSRI in Finland: comparison of cost-effectiveness betweenthe other SSRIs and SNRI for the treatment of depression andestimation of the budgetary impact. J Med Econ 2002;5:91–107
   Google Scholar
• Francois C, Toumi M, Aaakhus AM, Hansen K. A pharmacoconomicevaluation of escitalopram, a new selective serotoninreuptake inhibitor. Eur J Health Econ 2003;4:12–9
   PubMedGoogle Scholar
• Wade AG, Toumi I, Hemels MEH. A probabilistic cost-effectvenessanalysis of escitalopram, generic citalopram and venlafaxineas a first-line treatment of major depressive disorder in the UK.Curr Med Res Opinion 2005;21:631–41
   Google Scholar
• Kulp W, Schulenburg JMGV, Greiner W. Cost-effectiveness ofoutpatient treatment in depressive patients with escitalopram inGermany. Eur J Health Econ 2005;6:317–21
   Google Scholar
• Hemels MEH, Kasper S, Walter E, Einarson TR. Cost-effectivenessanalysis of escitalopram: a new SSRI in the first-line treatment ofmajor depressive disorder in Austria. Curr Med Res Opinion 2004;20:869–78
   PubMed Web of Science ®Google Scholar
• Baardewijk MV, Vis PMJ, Einarson TR. Cost effectiveness ofduloxetine compared with venlafaxine-XR in the treatment of majordepressive disorder. Curr Med Res Opinion 2005;21:1271–79
   Google Scholar
• Vis PM, Baardewijk MV, Einarson TR. Duloxetine and venlaaxine-XR in the treatment of major depressive disorder: ameta-analysis of randomized clinical trials. Ann Pharmacother 2005;39:1798–807
   Google Scholar
• Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safetyand tolerability of duloxetine in the treatment of majordepressive disorder: analysis of pooled data from eight placebocontrolledclinical trials. Hum Psychopharmacol Clin Exp 2005;20:327–41
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Raskin J, Wohlreich MM, et al. The efficacy ofduloxetine: a comprehensive summary of results from MMRMand LOCF_ANCOVA in eight clinical trials. BMC Psychiatry 2004;4:26
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Thieda P, et al. Comparative effectvenessof second-generation antidepressants in the pharmacologictreatment of adult depression. Agency for Healthcare Researchand Quality (AHRQ) Publication No. 07-EHC007-EF. January 2007
   Google Scholar